At a Glance
  • Status: Active Consortium
  • Year Launched: 2009
  • Initiating Organization: German Federal Ministry for Education and Research (BMBF)
  • Initiator Type: Government
  • Disease focus:
    Alzheimer's Disease, Epilepsy, Parkinson's Disease
  • Location: Europe


The Neuroallianz consortium consists of strategic research partnerships. Its focus is on therapeutic and diagnostic approaches to neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, or epilepsy derived from research on developing medicines. Neuroallianz focuses on the implementation of projects in the following areas: therapeutic projects, diagnostic projects, and support projects.


Neuroallianz has designed a new type of strategic partnership model, in which various academic institutions and companies work on a range of innovative diagnostic and therapeutic research projects. Its aim is to selectively and efficiently transform research into tangible benefits for patients. Its focus is on the diagnosis and treatment of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, or epilepsy.

Consortium History

2009-2015: Project duration

Structure & Governance

The project team consist of project manager, deputy project manager, and project team members who implement the project in accordance with the agreed upon project plan. The project manager and the project team members work in a collaborative, open, and transparent manner.

The Steering Committee coordinates, controls, and directs the progress of the Neuroallianz project portfolio, taking into account the BMBF requirements and strategic recommendations of the Strategic Advisory Board.

The Strategic Advisory Board consists of members with outstanding experience in industrial enterprises and/or academic institutions. Its mission is to provide strategic and scientific guidance for the research program.

A close and open cooperation between the partners ensures a successful processing of Neuroallianz projects. The consortium manager is responsible for coordination and management of the consortium members and their external representation.

The scientific coordinator of the University of Bonn supports the consortium manager in coordinating Neuroallianz activities at the University of Bonn.


The consortium budget is €40 million.

Points of Contact


Service provider for its own and third-party information partners of the Neuroallianz:

UCB Pharma GmbH
Alfred-Nobel-Straße 10
40789 Monheim
Managing Director: Peter Mitterhofer

Technical Contact
Stephan Spring Stubbe
phone: +49 (0) 2241 14 2337

Sponsors & Partners

Charite–University Berlin

Cube Biotech GmbH

Fraunhofer Society for the Promotion of Applied Research

Helmholtz-Zentrum Dresden-Rossendorf

IBL International GmbH

Immunogenetics AG

Life and Brain GmbH

Pharmacelsus GmbH

Piramal Imaging GmbH

Ratiopharm GmbH

Research Center Julich

ROTOP Pharmaceuticals AG

UCB Pharma GmbH

University of Bonn

University of Essen

University of Gottingen

University of Tubingen

Young Diagnostics GmbH

Last Updated: 04/21/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.